Response to " NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng

J Immunother Cancer. 2023 Jun;11(6):e007397. doi: 10.1136/jitc-2023-007397.

¹ Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA.
² Department of Medicine (Endocrinology and Metabolism), Yale University School of Medicine, New Haven, Connecticut, USA.
³ Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
⁴ Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA.
⁵ Department of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA Harriet.Kluger@Yale.edu.

No abstract available

Keywords: genetic markers; immune checkpoint inhibitors.

Publication types